Antisense therapy in the treatment of hypercholesterolemia

European Journal of Internal Medicine

Volumn 22, Issue 6, 2011, Pages 541-546

  Lippi, Giuseppe ^a   Favaloro, Emmanuel J ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

Antisense therapy; Atherosclerosis; Cardiovascular disease; Statins; Therapy

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ACYL COENZYME A; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN B100; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MIPOMERSEN; SQUALENE SYNTHASE INHIBITOR;

ANTISENSE THERAPY; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR RISK; CIGARETTE SMOKING; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; MUSCLE WEAKNESS; MYALGIA; NONHUMAN; PRIMARY PREVENTION; REVIEW; RHABDOMYOLYSIS; SECONDARY PREVENTION; SINGLE DRUG DOSE; VENOUS THROMBOEMBOLISM;

EID: 80855147605     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2011.06.015     Document Type: Short Survey

References (28)

1. World Health Organization World Health Statistics 2010 WHO Press 20 Avenue Appia, 1211 Geneva 27, Switzerland
2. V.L. Roger, A.S. Go, D.M. Lloyd-Jones, R.J. Adams, J.D. Berry, and T.M. Brown Heart disease and stroke statistics - 2011 update: a report from the American Heart Association Circulation 123 2011 e18 e209
3. D.J. Rader, J. Cohen, and H.H. Hobbs Monogenic hypercholesterolemia: new insights in pathogenesis and treatment J Clin Invest 111 2003 1795 1803 (Pubitemid 38057721)
4. G. Lippi, E.J. Favaloro, M. Montagnana, and M. Franchini C-reactive protein and venous thromboembolism: causal or casual association? Clin Chem Lab Med 48 2010 1693 1701
5. K.R. Feingold Does inhibition of apolipoprotein B synthesis produce foie gras? J Lipid Res 51 2010 877 878
6. G. Cervellin, I. Comelli, and G. Lippi Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features Clin Chem Lab Med 48 2010 749 756
7. G. Lippi, and G. Guidi Lipoprotein(a): an emerging cardiovascular risk factor Crit Rev Clin Lab Sci 40 2003 1 42 (Pubitemid 36250229)
8. G. Lippi, and G. Guidi Lipoprotein(a): from ancestral benefit to modern pathogen? QJM 93 2000 75 84 (Pubitemid 30098769)
9. G. Lippi, and G. Guidi Biochemical risk factors and patient's outcome: the case of lipoprotein(a) Clin Chim Acta 280 1999 59 71 (Pubitemid 29094582)
10. N. Kher, and J.D. Marsh Pathobiology of atherosclerosis - a brief review Semin Thromb Hemost 30 2004 665 672 (Pubitemid 40041602)
11. C. Potera Antisense-down, but not out Nat Biotechnol 25 2007 497 499
12. No authors listed Mipomersen Am J Cardiovasc Drugs 10 2010 271 279
13. J. Kling Safety signal dampens reception for mipomersen antisense Nat Biotechnol 28 2010 295 297
14. R.Z. Yu, T.W. Kim, A. Hong, T.A. Watanabe, H.J. Gaus, and R.S. Geary Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100 Drug Metab Dispos 35 2007 460 468 (Pubitemid 46333910)
15. J.J. Kastelein, M.K. Wedel, B.F. Baker, J. Su, J.D. Bradley, and R.Z. Yu Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B Circulation 114 2006 1729 1735 (Pubitemid 44607121)
16. E. Merki, M.J. Graham, A.E. Mullick, E.R. Miller, R.M. Crooke, and R.E. Pitas Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice Circulation 118 2008 743 753
17. F. Akdim, E.S. Stroes, E.J. Sijbrands, D.L. Tribble, M.D. Trip, and J.W. Jukema Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy J Am Coll Cardiol 55 2010 1611 1618
18. F. Akdim, M.E. Visser, D.L. Tribble, B.F. Baker, E.S. Stroes, and R. Yu Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia Am J Cardiol 105 2010 1413 1419
19. M.E. Visser, F. Akdim, D.L. Tribble, A.J. Nederveen, T.J. Kwoh, and J.J. Kastelein Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia J Lipid Res 51 2010 1057 1062
20. F.J. Raal, R.D. Santos, D.J. Blom, A.D. Marais, M.J. Charng, and W.C. Cromwell Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Lancet 375 2010 998 1006
21. R.M. Crooke, M.J. Graham, K.M. Lemonidis, C.P. Whipple, S. Koo, and R.J. Perera An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis J Lipid Res 46 2005 872 884
22. A.E. Mullick, W. Fu, M.J. Graham, R.G. Lee, D. Witchell, and T.A. Bell Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice J Lipid Res 52 2011 885 896
23. E.M. Straarup, N. Fisker, M. Hedtjärn, M.W. Lindholm, C. Rosenbohm, and V. Aarup Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates Nucleic Acids Res 38 2010 7100 7111
24. G. Lippi, M. Franchini, and G. Targher Screening and therapeutic management of lipoprotein(a) excess: Review of the epidemiological evidence, guidelines and recommendations Clin Chim Acta 412 2011 797 801
25. E. Merki, M. Graham, A. Taleb, G. Leibundgut, X. Yang, and E.R. Miller Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice J Am Coll Cardiol 57 2011 1611 1621
26. A. Poli, and A. Corsini Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: analysis of SEAS and JUPITER trials Eur J Intern Med 21 2010 372 373
27. R.Z. Yu, R.S. Geary, J.D. Flaim, G.C. Riley, D.L. Tribble, and A.A. vanVliet Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2′-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe Clin Pharmacokinet 48 2009 39 50
28. J. Kling Safety signal dampens reception for mipomersen antisense Nat Biotechnol 28 2010 295 297